Aliskiren: A novel renin inhibitor for hypertension

Indian Heart Journal

Volumn 60, Issue 1, 2008, Pages 69-72

  Tayal, Vandana ^a,b   Kalra, Bhupinder Singh ^a  

^a MAULANA AZAD MEDICAL COLLEGE   (India)

^b B 21 Tarang Apartments ^*  (India)

Author keywords

Aliskiren; Hypertension; Renin inhibitor; SPP100

Indexed keywords

ALISKIREN; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; IRBESARTAN; PLACEBO; RAMIPRIL; RENIN; RENIN INHIBITOR; VALSARTAN;

AREA UNDER THE CURVE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; ELECTROCARDIOGRAM; FATIGUE; HEADACHE; HUMAN; HYPERTENSION; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NORMAL HUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

AMIDES; FUMARATES; HUMANS; HYPERTENSION; RENIN;

EID: 48749085184     PISSN: 00194832     EISSN: 00194832     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Oparil S, Haber E. The renin-angiotensin system. N Engl J Med 1974;291:381-401,446-457.
2. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease, a unifying hypothesis. Hypertension 2001;37:1047-1052.
3. Gilbert RE, Krum H, Wilkinson-Berka J, Kelly DJ. The renin- angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations. Diabet Med 2003;20:607-621.
4. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997.
5. Bing J. Rapid marked increase in plasma renin in rats treated with inhibitors of the renin system. Effects of 1-sar-8-ala-angiotensin II and of a synthetic converting enzyme inhibitor (nonapeptide, SQ 20.881) on normal and adrenalectomized rats. Acta Pathol Microbiol Scand [A] 1973;81:376-378.
6. Hollenberg NK, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue: Evidence from comparative pharmacological interruption of the renin system. Hypertension 1998;32:387-392.
7. Nguyen G, Burckle CA. The (pro)renin receptor: biology and functional significance. Bull Acad Natl Med 2004;188:621-628.
8. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002;109:1417-1427.
9. Danser AHJ, Deinum J. Renin, prorenin, and the putative (pro)renin receptor. Hypertension 2005;46:1069-1076.
10. Rahuel J, Rasetti V, Maibaum J, et al. Structure-based drug design: the discovery of novel non peptide orally active inhibitors of human renin. Chem Biol 2000;7:493-504.
11. Azizi M, Menard J, Bissery A, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004;15:3126-33.
12. Azizi M, Webb R, Nussberger J, Hollenberg NK. Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 2006;24:243-56.
13. Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003; 42:1137-1143.
14. Mitchell J, Oh B, Herron J, et al. Once-daily aliskiren provides effective, smooth 24-hour blood pressure control in patients with hypertension. J Clin Hypertens 2006;8:209.
15. Vaidyanathan S, Jin Y, Schiller H, Jensen C. Aliskiren, a novel oral renin inhibitor, has no interaction with cytochrome P450 isoenzymes in vitro. Basic Res Pharmacol Toxicol 2005;97(Suppl 1):239.
16. Wood JM, Schnell CR, Cumin F, Menard J, Webb RL. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens 2005;23:417-26.
17. Tassell BWV, Munger MA. Aliskiren for renin inhibition: a new class of antihypertensives. Ann Pharmacother 2007;41:456-64.
18. Vaidyanathan S, Valencia J, Kemp C, et al. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int J Clin Pract 2006;60:1343-56.
19. Veniant M, Menard J, Bruneval P, Morley S, Gonzales MF, Mullins J. Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver. J Clin Invest 1996; 98:1966-1970.
20. Villamil A, Chrysant S, Calhoun D, Schober B, Hsu H, Zhang J. The novel oral renin inhibitor aliskiren provides effective blood pressure control in patients with hypertension when used alone or in combination with hydrochlorothiazide. J Clin Hypertens 2006;8(Suppl A):A100.
21. Taylor A, Tschope D, Kilo C, et al. Adding aliskiren to ramipril improves 24-hour blood pressure control compared to ramipril alone in patients with diabetes and hypertension. J Hypertens 2006;24(Suppl 4):S81.
22. Uresin Y, Taylor A, Kilo C, et al. Aliskiren, a novel renin inhibitor, has greater BP lowering than ramipril and additional BP lowering when combined with ramipril in patients with diabetes and hypertension. J Hypertens 2006;24(Suppl 4):S82.
23. Munger MA, Drummond W, Essop MR, Maboudian M, Khan M, Keefe DL. Aliskiren as add-on to amlodipine provides significant additional blood pressure lowering without increased oedema associated with doubling the amlodipine dose. Eur Heart J 2006;27(Suppl):117.
24. Veniant M, Menard J, Bruneval P, Morley S, Gonzales MF, Mullins J. Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver. J Clin Invest 1996;98:1966-1970.
25. Smithies O. Theodore Cooper Memorial Lecture. A mouse view of hypertension. Hypertension 1997;30:1318-24.
26. Herron J, Mitchell J, Oh B, et al. The novel renin inhibitor aliskiren is not associated with rebound effects on blood pressure or plasma renin activity following treatment withdrawal. J Clin Hypertens 2006;8(Suppl A):A86.